Release of basic fibroblast growth factor (bFGF) was investigated in bovine retinal endothelial cells (BREC) maintained in monolayer culture. Confluent cells released bFGF into serum-free culture medium or medium containing 5 % serum at rates of up to 105.2 and 61.3 pM/day respectively. bFGF release coincided with a decrease in monolayer cell number and increases in lactate dehydrogenase (LDH) concentration and cells and cell-debris particles in the medium, which suggested that cell damage and lysis were responsible for growth-factor release. Maximum bFGF release at 24 h (230+10 pM) occurred when the cells were treated with lipopolysaccharide (10 /eg/ml), which also produced the greatest changes in parameters of cell damage. Sub-confluent cells showed little overt damage at 24 h, but released bFGF (78 + 20 pM) along with LDH, indicating that some cell lysis had occurred. Insulin-like growth factor 1 (IGF-1) was also released into serum-free culture medium at a rate of 0.34 nM/day, but not into medium containing serum or when the cells were treated with lipopolysaccharide. This implies that the mechanism of IGF-1 release is different from that of bFGF and is not related to cell damage. Culture medium conditioned by BREC stimulated the proliferation of these cells, as measured by an increase in their incorporation of [methyl-3H] 
INTRODUCTION
Basic fibroblast growth factor (bFGF) is a polypeptide originally isolated from bovine pituitary and brain [1, 2] . It is one member of a family of growth factors characterized by their strong affinity for heparin, which includes acidic fibroblast growth factor [3] and some tumour-cell-derived factors [4, 5] . It was originally isolated independently from many cells and tissues and was given several names, e.g. eye-derived growth factor I [6] , heparin-binding growth factor ,B [7] and macrophage-derived growth factor [8] , all of which have been shown to be homologous to bFGF [9] .
Retinal extracts have been shown to contain bFGF [10] , and purified bFGF is a potent mitogen for bovine retinal endothelial cells (BREC) [11] . bFGF is also angiogenic in several models [12, 13] . Considerable interest has therefore developed as to its possible role in proliferative diabetic retinopathy. This condition is characterized by the growth of abnormal new blood vessels arising from existing retinal vessels [14] .
bFGF is present in the extracellular matrix of cells, where it is bound to heparan sulphate proteoglycans [15, 16] , and early reports suggested that it was not present in media conditioned by bovine aortic and corneal endothelial cells, although it could be extracted from these cells and from the matrix [17, 18] . When the gene for bFGF was cloned [19] , it was realized that the transcribed sequence did not contain a classical signal-peptide region allowing secretion from cells, and that in most tissues mRNA levels were very low, suggesting little bFGF production [20] .
The release of bFGF from extracellular matrix or from cells is required if it is to be implicated in either physiological or pathological angiogenesis. Two theories have been advanced, the first that extracellular matrix acts as a pool of bFGF which can be released in response to heparinitase enzymes [15, 21, 22] and the second that cell damage could cause the release of this growth factor from within the cell. Recently, injury-mediated release of bFGF has been demonstrated from bovine aortic endothelial cells [23] , and bFGF has been shown to be present in medium conditioned by BREC [24] , although it was not clear how release from these cells was mediated.
The aims of this study were (1) to examine the pattern of bFGF release from BREC with time, by using a radioimmunoassay, (2) to relate this release to parameters of cell damage and lysis, (3) to characterize biochemically the bFGF released, and (4) to measure its bioactivity with [methyl-3H]thymidine uptake as a marker of cell proliferation.
The cells were characterized by their cobblestone morphology and by uniform staining for Factor VIII-related antigen.
Growth-factor release from BREC monolayers Subconfluent BREC were treated with trypsin (0.25 %, w/v) (ICN Flow, Rickmansworth, Herts., U.K.), and a single-cell suspension was produced by passing cell clumps through a 21-gauge needle. An equal volume of this suspension was then added to each of 24 25 cm2 tissue-culture flasks previously treated with fibronectin, and the cells were grown in DMEM +10 % PDS. At confluence the medium was removed and the monolayer washed with Hanks Balanced Salt Solution (HBSS). Then 2 ml of serum-free DMEM containing 0.01 % (w/v) CHAPS [27] was added to each flask, and the flasks were sealed and incubated at 37°C; 21 flasks were used for measuring cumulative growth-factor release, and 3 for measuring daily release from the same monolayer, and subsequent results and discussion will refer to either serum-free cumulative or daily release. Photographs were taken of the cells every day (Fig. 1) . A further series of experiments was carried out on 21 25 cm2 flasks containing cells prepared identically with those above. At confluence the medium was removed, the monolayer washed with HBSS and 2 ml of DMEM containing 5 % (v/v) human serum (North London Blood Transfusion Centre, London N.W.9, U.K.) was added to each flask, and the flasks were sealed and incubated at 37 'C. These flasks are referred to as serumcontaining cumulative-release flasks. At zero time and every day for 6 days, three of the serum-free cumulative-release flasks, three of the serum-containing cumulative-release flasks and the three flasks used for measuring daily release had their medium removed and centrifuged at 670 g for 10 min. The medium from each flask was divided into four 0.5 ml portions, and these were stored frozen at -20 'C before growth-factor assays. Samples for growth-factor bioassay were prepared under sterile conditions by using medium removed from the serum-free cumulativerelease flasks. The remaining pellet of debris and cells was resuspended in 0.75 ml of HBSS and counted with a Coulter Counter (Coulter Electronics, Luton, U.K.). A 2 ml portion of fresh serum-free DMEM + 0.01 % CHAPS was added to each of the three flasks used for measuring daily release. Medium and debris were removed from these flasks each day and fresh serumfree DMEM + 0.01 0% CHAPS was added. The cell monolayer in the three serum-free and serum-containing cumulative-release flasks was washed with HBSS and treated with 1 ml of 0.25 % trypsin until all cells had detached. The cells were resuspended in 1 ml of HBSS and counted.
Growth-factor release from lipopolysaccharide-treated and sub-confluent BREC monolayers
Cell growth conditions were chosen in order to achieve minimum (sub-confluent growing cells) and maximum (addition of lipopolysaccharide) cell damage. BREC were plated into 25 cm2 flasks at either high density (600000 cells per flask) or low density (200000 cells per flask). The cells in the flasks seeded at high density were grown to confluence, whereas those seeded at low density were allowed to attach overnight at 37 'C (subconfluent flasks). Medium was then removed and the cells were washed with HBSS. A 2 ml portion of serum-free DMEM + 0.01 % CHAPS or of DMEM containing 50 human serum was added to the flasks containing the confluent cells, and lipopolysaccharide from Escherichia coli 055:B5 (10 ,tg/ml; Sigma, Poole, Dorset, U.K.) was added to half of the flasks in each group. A 1 ml portion of serum-free DMEM + 0.01 0% CHAPS or of DMEM containing 5o% human serum was added to the flasks containing the sub-confluent cells to achieve similar medium/cell ratios to those used for the confluent cells. All flasks were incubated at 37°C for 24 h. The medium was then removed and divided into batches, and the cells were trypsin-treated and counted as in the cumulative growth-factor-release experiments above except that the medium from the sub-confluent flasks was divided into 0.25 ml portions. Samples were stored at -20°C before growth-factor assays.
Iodination of bFGF
Recombinant bFGF (rbFGF) (Amersham, Aylesbury, Bucks., U.K.; 5 ,g) was iodinated with 1 mCi of Na'25I by using chloramine-T, and free 1251 separated on a heparin-Sepharose affinity column as previously described [28] . The The ethanol was removed, and the precipitated material was solubilized with 0.5 ml of 25 M-formic acid per well and then placed in 3.51ul of scintillation fluid (Optiphase Safe) (LKB/Pharmacia, Milton Keynes, U.K.). Each well was rinsed with 0.5 ml of PBSA, which was added to the appropriate scintillation vial. Vials were counted for radioactivity in a Beckman LS 1801 liquid-scintillation counter for 1 min per sample.
Identity of bFGF in BREC-conditioned medium bFGF in BREC-conditioned medium was characterized by its elution profile on a heparin-Sepharose column compared with that of rbFGF. Heparin-Sepharose was prepared by rehydration and washing in distilled water, followed by pre-equilibration with 0.05 M-Tris/HCl, pH 7.4, containing 0.15 M-NaCl. A column (1.0 cm x 6.0 cm) was packed with heparin-Sepharose, and either 1 ml ofrbFGF (305 pM) or 12 ml of BREC-conditioned medium (containing 4.7 pM-bFGF as measured by radioimmunoassay) was run on to the column. Heparin-binding growth factors were eluted from the column with a linear 0. 15-3 M gradient of NaCI in 0.05 M-Tris/HCI, pH 7.4, in a total of 120 ml (6 ml/fraction) for rbFGF, or 30 ml (1.5 ml/fraction) for BREC-conditioned medium in a total of 20 fractions. Fractions eluted from the column run with rbFGF were diluted l:20 with assay buffer for bFGF radioimmunoassay, whereas fractions from the column run with BREC-conditioned medium were dialysed overnight at 4°C against 0.05 M-Tris/HCl, pH 7.4, and assayed neat against rbFGF standards prepared in 0.05 MTris/HCl, pH 7.4, containing 0.15 M-NaCl which had been run through the heparin-Sepharose column before sample application and dialysed. medium. Also several smaller beads and many small dark particles can be seen; these are the components of cell debris. On day 4 the monolayer appears severely disrupted, with many dead cells and cell-debris particles; however, at this stage it is predominantly intact. Finally, on day 6 there is the complete break-up of the monolayer, with large gaps between the endothelial cells, seen on the bottom left of the micrograph (Fig.  1d) , and an increased amount of cellular debris. Confluent cell monolayers in medium containing serum showed a different pattern of changes in monolayer cell number compared with that in serum-free medium. There was an initial fall from 6.5(±0.1)x 106 to 6.1 (±0.4)x 105 cells per flask, but the number then increased to 7.8 (+0.4) x 105 cells per flask after 48 h before falling to the values seen in serum-free medium by day 5 . The early increase could be explained by unsustained cell proliferation in response to released growth factors. Monolayer disruption, as viewed through the microscope, was similar to that seen in serum-free medium.
Release of cells from the monolayer and increase in cell debris in serum-free and serum-containing culture medium
There was an increase in the number of cells present in serumfree culture medium as measured with the Coulter Counter (Fig.  3) , which coincided with a decrease in cell number in the BREC monolayer. There was a greater rate of increase in particles counted in the medium, 5.2 (± 0.2) x 105 counts per flask per day over the first 4 days compared with the decrease in cells in the monolayer of 0.57 (± 0.15) x 105 cells per flask per day over the same period. There was also no further decrease in monolayer cell number over the last 2 days, whereas the cell and debris count in the medium continued to increase by 2.3 (+0.9) x I05 counts per flask per day. These results could be partly explained by cell proliferation in the monolayer, but there is also considerable break-up of cells into smaller fragments, as seen in the photographic record (Fig. 1 ). Cells and cell-debris particles measured in serum-containing culture medium increased at a lower rate [2.6 (+ 0.6) x I05 counts per flask] than in serum-free medium, and this could be explained by less cell damage. Monolayer cell number, however, eventually decreased to the levels seen in serum-free medium, indicating that similar monolayer damage did occur in serum-containing medium, and a better explanation is that there was less break-up of released cells into smaller fragments. The respectively. bFGF was released at rates of 49 and 177 pM/day in the daily-release flasks.
IGF-1 release into serum-free and serum-containing culture medium
The results for IGF-1 release are shown in Fig. 5 ; all results are means + S.E.M. of data from three separate experiments. IGF-1 was released into serum-free DMEM by BREC monolayers at a rate of 0.34 + 0.02 nM/day, reaching a maximum of 2.56 nm. The release rate of IGF-1 in the daily-release flasks was 0.75 + 0.05 nM/day. A baseline level of IGF-1 of 2.50 + 0.28 nm, owing to the presence of IGF-1 in serum, was seen in serumcontaining culture medium, and there was no significant increase in IGF-1 concentration over the time course of the experiment.
LDH release into serum-free and serum-containing culture medium
The results for LDH release are shown in Fig. 6 ; all results are means + S.E.M. of data from three separate experiments. LDH release into serum-free DMEM by BREC followed a rate of 105 units/litre per day, to reach a maximum of 628 units/litre. A constant release of 90 + 7 units/litre per day was seen in the same monolayer when fresh medium was added daily. LDH was released into serum-containing medium at a rate of 110 units/litre per day, reaching a maximum of 689 units/litre. This was similar to the pattern of release seen in serum-free medium, indicating a comparable amount of cell lysis in cell monolayers maintained with or without the addition of serum.
Growth-factor release from lipopolysaccharide-treated and sub-confluent BREC monolayers bFGF release after 24 h from sub-confluent BREC and confluent cells with or without lipopolysaccharide (10 ug/ml) into both serum-free and serum-containing medium is shown in Medium from serum-free cumulative-release flasks sampled on days 1-6 produced increased [3H]thymidine uptake into BREC as compared with medium sampled at zero time (Table 1) . bFGF (5 pM) also gave a significant stimulation of [3H]thymidine uptake.
Identity of bFGF in BREC-conditioned medium
To confirm the identity of the bFGF measured in the radioimmunoassay, the heparin-Sepharose elution profile of BRECconditioned medium was compared with that of rbFGF. The rbFGF was eluted at 1.9 M-NaCI, reaching a peak at 2.2 M. Recovery as a percentage of rbFGF applied to the column was 34.3 %. BREC-conditioned medium from serum-free cumulativerelease flasks was eluted as three peaks at 0.15 M-, 0.8 M-and 2.3 M-NaCl, the final peak corresponding to the elution position of rbFGF (Fig. 8) .
DISCUSSION
Retinal endothelial-cell proliferation is a requirement for new vessel growth as seen in proliferative diabetic retinopathy. The stimulus to this proliferation has not been determined, although the development of large areas of ischaemic retina usually precedes this event. We have shown that in monolayer culture BREC release large quantities of bFGF, which is a potent mitogen for these cells. The maximum release of bFGF from these monolayers into serum-free medium is 105.2 pM/day and into serum-containing medium is 61.3 pM/day; this compares with an ED50 for the stimulation of BREC proliferation by rbFGF of 2.8 pM (R. A. Brooks, unpublished work) and by purified bFGF of 0.8 pM [1 1] and 5.5 pM [24] . The amount of bFGF released by BREC monolayers is therefore in excess of that required to bring about retinal endothelial-cell proliferation. We have also shown that serum-free DMEM + 0.01 % CHAPS conditioned by BREC monolayers is mitogenic for BREC, and this ability to stimulate BREC proliferation is similar to that shown by rbFGF (5 pM).
The lack of a classic signal-peptide sequence on the mRNA transcript coding for bFGF, which would allow secretion, has led to speculation as to the source of bFGF measured in endothelial-cell-conditioned culture medium. Several authors have suggested that bFGF is mainly stored in the extracellular matrix, where it is bound to heparan sulphate proteoglycans [15, 16, 18, 21] and can be released by heparinitase and heparin [15, 22] . Others have shown release of bFGF in viable confluent cultures of bovine corneal endothelial cells [30] and BREC [24] by an unknown mechanism. Rifkin & Moscatelli [31] have pointed out that, even in viable cultures, there is a small amount of cell death, and this could be responsible for the measurable bFGF. Endothelial cells from bovine aorta, adrenal capillaries and retinal vessels have been shown to contain extractable bFGF [17, 24] . Using bovine aortic endothelial cells, Gajdusek & Carbon [23] demonstrated the presence of large quantities of bFGF, which can be released by cell lysis and then bind to extracellular matrix, where it could be released by heparin and the enzyme heparinitase.
We have now shown the release of bFGF from bovine retinal endothelial cells into both serum-free and serum-containing medium and related this to parameters of cell damage and lysis. In serum-free medium, bFGF increases along with a decrease in cell number in the monolayer. Its release is also associated with increased cells and cell debris in the culture medium and with release of the enzyme LDH, which provides a marker of cell lysis [32] . The quantity of bFGF released was variable and was dependent on the batch of cells used. The quantity of cells and debris in the medium increased more rapidly than the decrease in monolayer cell number. This could be due to either cell proliferation in the monolayer or degradation of released cells, and, although the former cannot be ruled out, the appearance of small particles in the conditioned medium indicates that cell break-up did occur. Additionally, the serum-free medium in these flasks would not readily support the proliferation of retinal endothelial cells even in the presence of released growth factors. In serumcontaining medium, bFGF release can also be linked to parameters of cell damage and lysis. Although there is an initial increase in monolayer cell number and a less marked linear increase in cell debris in the medium, owing to less cell break-up, LDH release was similar to that seen in serum-free medium, indicating that cell lysis did occur. The fact that LDH concentration increases linearly to day 6 in both serum-free and serum-containing medium, whereas bFGF release forms a plateau after day 4, is probably due to progressive degradation of bFGF by proteases released from damaged cells, leaving it unable to bind to the antibody in the radioimmunoassay.
In order to investigate more rigorously the relationship between cell damage, lysis and bFGF release, cell growth conditions were chosen to produce minimum (sub-confluent cells) and maximum (lipopolysaccharide-treated cells) cell damage. Endotoxin-mediated cell damage has been used previously to investigate the release of growth-promoting activity from bovine aortic endothelial cells [23] . Release of bFGF in both serum-free and serum-containing medium was greatest when cells were treated with lipopolysaccharide, which also produced the largest decrease in monolayer cell number and increase in cell debris and LDH concentration in the medium. A lower but significant release of bFGF was also seen when serum-free or serumcontaining DMEM was conditioned by sub-confluent BREC monolayers. Although there were few cell-debris particles released into the medium, indicating little cell break-up, LDH was released in quantities approaching those seen from confluent monolayers, showing that cell lysis had occurred. This would provide an explanation for bFGF release. Insufficient extracellular matrix was produced by these cells, under the experimental conditions used, to allow extraction and measurement of bFGF. The absence of this means of bFGF sequestration may have increased the measurable concentration of this growth factor in BREC-conditioned medium. The identity of bFGF released from the monolayer was shown by heparin-Sepharose affinity chromatography. The concentration of NaCl at which both rbFGF and bFGF in BRECconditioned medium are eluted from the column is higher than that observed by other investigators [17, 33] . However, these values have been shown to be very dependent on the batch of heparin-Sepharose used [34] . Two other peaks of bFGF immunoreactivity were observed in the elution profile of BRECconditioned medium, at 0.15 M-and 0.8 M-NaCl. The first of these could correspond to the weakly bound high-molecularmass fraction observed by Courty et al. [6] in retinal extract and the second to acidic FGF. If this were due to cross-reactivity of acidic FGF in the radioimmunoassay, then it would imply very high concentrations of acidic FGF in BREC-conditioned medium. Baird et al. [35] have reported that bFGF can be coeluted with a low-salt fraction from a heparin-Sepharose column, and this is a more likely explanation.
At the end of each experiment, the flasks to which serum-free DMEM + 0.01 % CHAPS had been added daily showed more disruption to the BREC monolayer than in the flasks used for measuring serum-free cumulative growth-factor release, but the number of cells remaining in the monolayer was similar. The cumulative cell and debris count in the serum-free medium and the LDH levels were the same in both sets of flasks, as was IGF-1 release until levels reached a plateau. This plateau could be due to a cessation of IGF-1 release in these flasks or to degradation of IGF-1 by proteases released from the lysed cells.
IGF-1 may contribute to the retinal endothelial-cell proliferation seen in proliferative diabetic retinopathy. It has been shown by King et al. [36] to be mitogenic for retinal endothelial cells in culture, and it can interact with bFGF in stimulating the progression of cells through the cell cycle [37] . Hyer et al. [38] showed a transient rise in the serum level of IGF-1 in diabetics at the time of new vessel growth, which returned to normal levels after successful laser treatment, suggesting a role for IGF-1 in vivo. We have shown that IGF-1 is released from BREC monolayers into serum-free medium; however, there was no release into serum-containing medium or when the cells were damaged by the addition of lipopolysaccharide. These results suggest that IGF-1 is not released from damaged BREC. The fact that IGF-1 can be conventionally secreted from cells [39] suggest this as a likely explanation for its release into serum-free medium. In serum-containing medium, there may be negative feedback on release owing to the presence of IGF-1 in the serum.
Both bFGF and IGF-1 have been reported to be elevated in the vitreous of patients with proliferative diabetic retinopathy [40, 41] . Our results show that both of these growth factors can be released from BREC, but that their mechanism of release is different. IGF-I is likely to be secreted, whereas bFGF is released after cell damage and lysis, although this does not preclude additional release of bFGF from viable cells by an as yet unknown mechanism. Retinal capillary damage is a feature of advanced diabetic retinopathy, and further endothelial-cell damage could occur in the ischaemic retina before neovascularization. Although not wishing to exclude the contribution of growth factors released from other retinal cells, our results are further evidence for the involvement of bFGF in this sight-threatening condition.
